Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biodesix Inc (BDSX)

Biodesix Inc (BDSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 184,549
  • Shares Outstanding, K 9,858
  • Annual Sales, $ 88,500 K
  • Annual Income, $ -35,270 K
  • EBIT $ -28 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.59
  • Price/Sales 2.16
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 85.41%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,262.70% on 07/14/25
  • IV Low 0.00% on 03/09/26
  • Expected Move (DTE 0) 0.09 (1.05%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 4
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,272
  • Open Int (30-Day) 1,267
  • Expected Range 8.04 to 8.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.26
  • Number of Estimates 1
  • High Estimate -1.26
  • Low Estimate -1.26
  • Prior Year -1.60
  • Growth Rate Est. (year over year) +21.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.83 +94.00%
on 02/12/26
19.71 -3.25%
on 03/09/26
+8.72 (+84.25%)
since 02/11/26
3-Month
5.26 +262.55%
on 01/09/26
19.71 -3.25%
on 03/09/26
+11.05 (+137.78%)
since 12/11/25
52-Week
3.44 +455.01%
on 05/15/25
19.71 -3.25%
on 03/09/26
+2.75 (+16.84%)
since 03/11/25

Most Recent Stories

More News
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million,...

BDSX : 19.07 (+1.87%)
Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team will participate...

BDSX : 19.07 (+1.87%)
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc.  (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth...

BDSX : 19.07 (+1.87%)
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in...

BDSX : 19.07 (+1.87%)
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Clinical utility data for Nodify Lung ® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for...

BDSX : 19.07 (+1.87%)
Biodesix Announces Third Quarter 2025 Results and Highlights

Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86...

BDSX : 19.07 (+1.87%)
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

LOUISVILLE, Colo., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces its Corporate and Scientific presentations, and exhibitor presence...

BDSX : 19.07 (+1.87%)
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays

LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which...

BDSX : 19.07 (+1.87%)
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter...

BDSX : 19.07 (+1.87%)
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST...

BDSX : 19.07 (+1.87%)

Business Summary

Biodesix Inc. is a data-driven diagnostic solutions company. It offers blood-based tests across the lung cancer continuum of care. The company also offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as develops and commercializes...

See More

Key Turning Points

3rd Resistance Point 20.52
2nd Resistance Point 19.88
1st Resistance Point 19.48
Last Price 19.07
1st Support Level 18.44
2nd Support Level 17.80
3rd Support Level 17.40

See More

52-Week High 19.71
Last Price 19.07
Fibonacci 61.8% 13.49
Fibonacci 50% 11.57
Fibonacci 38.2% 9.65
52-Week Low 3.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar